Cellectar Biosciences, Inc. CLRB
1.21 USD -0.01 (-0.82%)
At closeNov 11, 2026, 4:00 PM EST
1.19 -0.02 -1.65%
After hours · Nov 11, 4:00 PM ET
1.19 Day range 1.30
1.11 52-week range 4.70
- YTD
- -58.98%
- 1 year
- -66.01%
News
seekingalpha.com Cellectar Biosciences, Inc. (CLRB) Q3 2026 Earnings Call Transcript Cellectar Biosciences, Inc. ( CLRB ) Q3 2026 Earnings Call November 10, 2026 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor…
benzinga.com Cellectar Biosciences Q3 2026 Earnings Call Transcript Cellectar Biosciences (NASDAQ:CLRB) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
globenewswire.com Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström…
benzinga.com Cellectar Biosciences Q3 EPS $(0.46) Beats $(0.56) Estimate Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.56) by 17.86 percent. This is a 67.38 percent increase over losses…
benzinga.com Cellectar Biosciences To Present Three Posters For Its Radiopharmaceutical Candidate At American Society Of Hematology Annual Meeting Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters…
benzinga.com Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131 Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential…